| Â | VIA only | VIA/VILI |
careHPV@ 1.0 pg/ml |
careHPV@ 0.5 pg/ml | Colposcopy |
|---|
Sensitivity | 41% | 58% | 84% (provider) 73% (self) | 90% (provider) 81% (self) | 81% |
Specificity | 95% | 82% | 88% (provider) 88% (self) | 84% (provider) 82% (self) | 77% |
- †Note that this table summarises the finding for sensitivity and specificity in the original study populations, taking into account the relative proportions of CIN1, 2 and 3 in the population. However, the model implementation used these data to derive a test probability matrix separately describing the relationship between each health state (Normal; PCR HPV positive; CIN1, CIN2, CIN3+, etc.) and each test, rather than utilising the study sensitivity and specificity estimates directly, as described in the text [3, 5, 6].
